Aims/hypothesis Gene polymorphisms of TCF7L2 are associated with increased risk of type 2 diabetes and transcription factor 7-like 2 (TCF7L2) plays a role in hepatic glucose metabolism. We therefore addressed the impact of TCF7L2 isoforms on hepatocyte nuclear factor 4α (HNF4α) and the regulation of gluconeogenesis genes.
Introduction
DNA or single-nucleotide polymorphisms (SNPs) in the gene encoding the WNT-signalling transcription factor, transcription factor 7-like 2 (TCF7L2), confer the largest genetic risk known so far for common forms of type 2 diabetes as described in a review by others [1] . Type 2 diabetes-associated TCF7L2 SNPs have been associated with impaired pancreatic beta cell function, e.g. reduced insulin exocytosis [2] , and a reduction in glucagon-like peptide-1-induced insulin secretion [3] [4] [5] . Human carriers of the TCF7L2 rs7903146 risk allele have increased pancreatic islet size, and altered alpha:beta cell ratios and distribution within pancreatic islets [6] . DNA sequences around the TCF7L2 rs7903146 SNP contain regulatory elements that are critical in the regulation of TCF7L2 transcription, suggesting that the type 2 diabetes susceptibility conferred by this locus is related to modified TCF7L2 expression [7] . At least 20 different TCF7L2 splice variants and isoforms exist (Table 1) [8] [9] [10] [11] [12] , which may also differ in their transcriptional activation properties [12] [13] [14] . We have previously shown that altered TCF7L2 splice variants in the pancreas exert different effects on pancreatic insulin secretion and islet survival [12] . In particular, the medium C-terminal TCF7L2 isoforms T1 and T2 are pro-apoptotic, while the short T3 and medium C-terminal T7 isoforms improve pancreatic beta cell survival and function.
Human carriers of the TCF7L2 rs7903146 risk T allele have also been reported to have elevated hepatic glucose production [15] [16] [17] [18] . An initial study of alternatively spliced Mature mRNA transcript Transcript number N-terminal C-terminal TCF4 nomination [13] Major pancreatic and liver TCF7L2 isoforms [12 [19] . TCF7L2 expression is highest in pericentral hepatocytes, where gluconeogenesis is low [20] . As evidence that TCF7L2 affects liver glucose metabolism [20] [21] [22] is accumulating, we sought to further characterise the expression of alternative human TCF7L2 transcripts in livers of normoglycaemic and type 2 diabetes individuals genotyped for rs7903146. We also analysed expression levels of these transcripts in HepG2 cells incubated with different glucose concentrations in the presence or not of insulin, as well as the mRNA expression of 84 genes related to glucose metabolism, subsequent to downregulation of TCF7L2 by small interfering RNA (siRNA). Hepatic gluconeogenesis is tightly controlled by rate-limiting enzymes, such as glucose-6-phosphatase (G6PC) and phosphoenolpyruvate carboxykinase, which are both inhibited by a TCF7L2-dependent pathway [20] [21] [22] . Hepatocyte nuclear factor 4α (HNF4α) and forkhead box O1 (FOXO1) are transcriptional regulators of G6PC, which mediates regulation of gluconeogenesis in response to feeding or fasting [23] . FOXO1 may compete for β-catenin binding with TCF7L2 under low glucose conditions [22, 24] . Therefore, we analysed whether TCF7L2 isoforms differentially affect the HNF4α-FOXO1 pathway in the transcriptional regulation of G6PC. Our findings, in particular the exclusive interaction of TCF7L2 isoforms T6 and T8 with HNF4α protein, suggest a distinct role for alternative TCF7L2 transcripts.
Methods
Patients We analysed liver samples from white morbidly obese French patients who underwent abdominal surgery and were included in the Biological Atlas of Severe Obesity (ABOS) cohort realised at the Centre Hospitalier Régional Universitaire de Lille, France (ClinicalGov NCT01129297) ( Table 2) . Informed consent was obtained from all individuals and the experimental design was approved by the Hospital's Ethics Committee. Type 2 diabetic patients were defined by fasting plasma glucose levels ≥7.0 mmol/l and/or current treatment for diabetes; normoglycaemic individuals were defined by fasting glucose levels of <5.6 mmol/l. All patients underwent preoperative evaluation (medical history and physical examination) and were devoid of any condition that could have increased abdominal surgery risks. The majority of patients suffered from obesity-related complications, like arthrosis and hypertension. Liver biopsies were immediately frozen in liquid nitrogen and stored at −85°C. A total of 250 individuals were genotyped for variant rs7903146 using Taqman SNP-assay C_29347861_10 on a 7900 HT Sequencer (Applied Biosystems/Life Technologies, Saint Aubin, France), following the manufacturer's instructions. The genotyping error rate was 0% as previously confirmed by automated sequencing using 768 duplicates [25] . Samples from all homozygous risk allele carriers (TT) were selected and equivalent numbers of individuals were selected from the other rs7903146 genotype classes (CC and CT) to have balanced groups. To minimise potential confounding factors, these individuals were selected within similar age and BMI ranges and sex [12] (FuGENE HD; Roche Diagnostics, Mannheim, Germany). RNA analyses were performed 48 h after transfection. For gene reporter assays, cells were lysed with passive lysis buffer (Promega, Charbonnieres, France) and luciferase activities were measured by a dual luciferase reporter assay system (Promega) with a luminometer (Centro LB 960; Berthold, Thoiry, France). Firefly luciferase activity was normalised to Renilla luciferase activity and results expressed relative to control.
Co-immunoprecipitation and western blot analysis HepG2 cells were transfected with the previously described ( [12] ) TCF7L2 splice variants (Fig. 1a ) using a transfection agent according to the manufacturer's instructions (FuGENE HD; Roche Diagnostics). Alternative liver TCF7L2 transcripts are listed in Table 1 . The T3 and T5 constructs both have a short C-terminal end that includes exon 14, which encodes a CRARF cysteine clamp (C-clamp) domain, but they differ in exon 4, which encodes 23 amino acids. The T1, T2 and T7 constructs have a medium C-terminal end and no C-clamp domain, but T1 and T2 contain exon 4; T1 also contains exon 13, which encodes 17 amino acids, and T2 and T7 contain the alternative exon 7b, which encodes the LVPQ motif [26, 27] . All T6, T8, T4 and T9 constructs have a long C-terminal end and no exon 4, but do have either exon 14, which encodes a CRARF (T8, T4, T9), or exon 15, which encodes a CRALF (T6) C-clamp domain. Constructs T4 and T9 also have exon 13, and T4 has the longer exon 7b.
The co-immunoprecipitation protocol was performed as previously described [28] . Briefly, cells were lysed for 30 min on ice with a 50 mmol/l Tris HCl (pH 8.0) buffer containing 150 mmol/l NaCl, 5 mmol/l EGTA, 50 mmol/l NaF, 10% vol./vol. glycerol, 1.5 mmol/l MgCl 2 , 1% vol./vol. Triton X-100 and freshly added 1× protease inhibitor cocktail (Complete; Roche Diagnostics). Protein lysates (2 mg) were clarified by 5 min centrifugation at 12,000 g and 4°C, and incubated overnight at 4°C with 5 μg of the following antibodies: normal rabbit immunoglobulin G (2729; Cell Signaling Technology, Danvers, MA, USA); and rabbit anti-HNF4α (H-171, sc-8987; Santa Cruz Biotechnology, Santa Cruz, CA, USA). Thereafter, 50 μl protein magnetic beads (A/G Dynal; Invitrogen/Life Technologies), previously washed with 2% wt/vol. BSA in PBS, were added to the incubation medium for 1 h. Co-immunoprecipitates were washed four times with 50 mmol/l Tris HCl (pH 8.0) buffer containing 150 mmol/l NaCl, 5 mmol/l EGTA and 1% vol./vol. NP-40, followed by boiling for 10 min in SDS-sample buffer. Proteins were applied to 6% SDS-PAGE and western blot immunolabelling performed with mouse monoclonal anti-HNF4α (PP-K9218-00; R&D Systems, Lille, France) or goat anti-TCF7L2 (TCF-4[N20], sc-8631; Santa Cruz). Other antibodies used for western blot immunolabelling were mouse anti-β-actin (sc-1616; Santa Cruz) and rabbit anti-β-tubulin (2148; Cell Signaling). Proteins were visualised with a western blot detection system (Amersham ECL; GE Healthcare, Freiburg, Germany). CC  CT  TT  CC  CT  TT  NGT  T2D   CC  CT  TT  CC  CT  TT  NGT  T2D   CC  CT  TT  CC  CT  TT Results Expression of several TCF7L2 alternative transcripts is increased in livers of normoglycaemic carriers of the rs7903146 risk allele and in those of type 2 diabetes individuals We identified nine TCF7L2 homozygous risk allele carriers (TT) in the normoglycaemic group and nine among type 2 diabetes individuals from ABOS; they were compared with individuals of wild-type (CC) and heterozygous (CT) genotypes ( Table 2) . As previously shown [12] , nine major TCF7L2 transcripts are expressed in the human liver and can be divided into three classes according to the length of their protein C-terminal end (short, medium and long) (Fig. 1a) . We examined transcript expression in 64 liver samples using quantitative real-time PCR assays specific to the presence of exon junctions. Several assays measured a combination of TCF7L2 transcripts with the same exon junction (ESM Fig. 1b) .
Statistical analyses
First, we compared TCF7L2 expression in type 2 diabetic vs normoglycaemic individuals irrespective of their genotype and differences of age (Mann-Whitney tests) (Fig. 1d, g, j, m, p) . Total TCF7L2 expression was similar in type 2 diabetic vs normoglycaemic individuals (exons 7 to 8; including transcription start site [TSS] 1 to 3 transcripts). TCF7L2 transcripts with TSS1 showed a significant increase in type 2 diabetic individuals compared with normoglycaemic individuals, as did transcripts containing exons 13-14, 13-17, 12-14 and 14-17 (Fig. 1m, p, j, ESM Fig. 1γ) ; this represents all transcripts, except T1 and T6. Alternative C-terminal transcripts containing exons 12-15 (T6), 12-17 (T1) and 14-15 (T3, T5) may have had slightly decreased expression, but were not significantly different expressed in type 2 diabetes vs normoglycaemic individuals (ESM Fig. 1t, w, z) . Linear regression analysis of TCF7L2 expression in type 2 diabetes vs normoglycaemic individuals, with age, BMI and sex as covariates, showed that the observed differences were only significant (p<0.05) when excluding samples from homozygous risk allele carriers (TT), in whom expression was similar in both groups. The combination of the observed exon junction expression values suggests that in type 2 diabetes individuals expression is increased in five of nine TCF7L2 transcripts (T2, T7, T8, T4 and T9).
Next, we compared TCF7L2 expression in relation to the presence of the rs7903146 risk allele in the normoglycaemic and type 2 diabetes groups (Fig. 1, ESM Fig. 1 ). In normoglycaemic individuals carrying two rs7903146 risk alleles, the overall TCF7L2 (exon 7-8) assay, as well as eight alternative transcript assays, showed significantly increased expression (Fig. 1e, h, k, n, ESM Fig. 1l, r, u, x, α) . Analysis of TCF7L2 expression in a linear regression model, with rs7903146 genotype, age, BMI and sex as covariates, generated similar results (p<0.05). In livers of type 2 diabetes individuals, where expression of TCF7L2 was increased on average compared with normoglycaemic individuals, the expression of splice variants was similar in all genotypes (Fig. 1c, f, i, l, o, ESM Fig. 1j, m, p, s, v, y, β) . These results suggest that having type 2 diabetes or carrying the rs7903146 risk allele is associated with increased liver TCF7L2 transcript expression, but that individuals carrying two risk alleles have higher expression levels, regardless of whether they suffer from diabetes or not.
Glucose and insulin affect TCF7L2 splice variant expression in HepG2 cells To analyse whether the liver TCF7L2 transcripts correlating with TCF7L2 rs7903146 and type 2 diabetes also play a role in liver glucose metabolism, their expression was examined in human liver HepG2 cells. First, we established that this cell line is heterozygous for rs7903146 (ESM Fig. 2a) . The induction of liver pyruvate kinase mRNA expression by glucose showed that genes related to glucose metabolism can indeed be induced in glucose-depleted HepG2 cells (data not shown). When incubated in the presence of 100 nmol/l insulin and either 1, 5 or 11 mmol/l glucose for 24 h, the full-length TCF7L2 transcript showed significantly increased expression compared with incubation in 1 mmol/l glucose alone (TSS1, exon 7-8) (Fig. 2a, b) , (exon 11-12) (ESM Fig. 2b) . A similar induced expression pattern was observed for alternative TCF7L2 transcripts with exon junctions 4-5 (representing T1, T2, T3) (ESM Fig. 2c ), 12-14 (T8) (Fig. 2c) , 12-17 (T1) (Fig. 2d) , 12-15 (T6) (ESM Fig. 2d ) and 14-17 (T4, T8, T9) (ESM Fig. 2e ). In addition, the expression of TCF7L2 transcripts with exon junctions 14-15 (T3, T5) (Fig. 2f) , 13-17 (T2, T7) (ESM Fig. 2e ) and 13-14 (T3, T5, T4, T9) (ESM Fig. 2f ) was increased in a glucose doseresponsive manner (all major transcripts with exon 13). Since changes in mRNA expression do not always correlate with protein expression, we also performed western blot analysis (Fig. 2g, h ). Levels of TCF7L2 isoforms with a molecular mass of 58 and 78 kDa were increased by the presence of 100 nmol/l insulin upon incubation of HepG2 cells with 1 or 5 mmol/l glucose. At 11 mmol/l glucose incubation, protein expression was increased in the 58 and 78 kDa isoforms, compared with incubation at 1 and 5 mmol/l glucose (Fig. 2g) , and we also observed weak induction of additional ∼65 kDa TCF7L2 proteins (Fig. 2g, h ). Our results show that TCF7L2 mRNA and TCF7L2 protein expression is increased in HepG2 cells by incubation with high glucose and insulin.
TCF7L2 represses a large set of genes that regulate gluconeogenesis To further analyse TCF7L2's role in liver glucose metabolism, we decreased TCF7L2 expression in HepG2 cells by siRNA and analysed the mRNA expression of 84 genes related to glucose metabolism (SABioscience QPCR pathway-focused array PAHS006, Qiagen Courtaboeuf, France). HepG2 cells were cultured either with 1 mmol/l glucose without insulin (with siRNA negative control or TCF7L2) or with 11 mmol/l glucose with 100 nmol/l insulin (with siRNA negative control or TCF7L2). As expected, in HepG2 cells cultured with insulin the expression of gluconeogenesis-stimulating genes (e.g. G6PC, PCK1) was lower and that of genes linked to glycolysis (e.g. PFKL, PKLR) higher than when incubated with glucose alone (ESM Fig. 3a) . In HepG2 cells incubated with 1 mmol/l glucose, 29 genes related to glucose metabolism showed a ±1.5-fold change in expression when TCF7L2 was downregulated by siRNA (ESM Fig. 3b, c) . We also analysed the expression of G6PC and PCK1 in TCF7L2 siRNA-transfected HepG2 cells incubated with 1, 5 or 11 mmol/l glucose, with or without 100 nmol/l insulin (Fig. 3) . As previously described for G6PC [29] , we observed a dose-dependent increase of mRNA expression by glucose, which was decreased by insulin (Fig. 3a, c) . siRNA-mediated downregulation of TCF7L2 expression significantly increased expression of G6PC and PCK1, independently of insulin (Fig. 3b, d ).
Glucose-6-phosphatase gene expression is repressed by TCF7L2 independently of FOXO1 Expression of G6PC is regulated by FOXO1 and HNF4α [30] , and the β-catenin-FOXO1 complex stimulates G6PC only in the absence of insulin [24] . We observed that in HepG2 cells with reduced TCF7L2 expression, G6PC mRNA expression was increased independently of the presence or absence of insulin (Fig. 3b, d) , suggesting that the regulation of G6PC by TCF7L2 may be independent of FOXO1. This prompted us to analyse FOXO1 and HNF4A expression in our experimental conditions. FOXO1 mRNA expression was unchanged when TCF7L2 was downregulated by siRNA transfection (Fig. 4a) . Moreover, although TCF7L2 may bind to distant enhancer elements of HNF4A to regulate its expression [31] , HNF4A mRNA expression was not altered by TCF7L2 siRNA in our study (Fig. 4a) . To further characterise the effect of TCF7L2 on G6PC expression, we measured G6PC promoter activity by using luciferase reporter constructs previously used to analyse the synergistic activation of HNF4α and FOXO1 [30] . In HepG2 cells treated with TCF7L2 siRNA, both the wild-type G6PC promoter and the G6PC promoter construct lacking the FOXO1 binding region (G6PCΔ123) showed a Representative western blots of total cell lysate from HepG2 cells cultured as above (a-f) similar increase in luciferase activity (Fig. 4b) , confirming that FOXO1 is not involved in TCF7L2-mediated repression of G6PC expression. Analysis of HNF4α protein levels in these cell lysates revealed an increase of HNF4α protein upon downregulation of TCF7L2 by siRNA transfection (data not shown). In additional experiments, we confirmed that TCF7L2 downregulation increases the accumulation of nuclear HNF4α protein in HepG2 cells cultured with 1, 5 and 11 mmol/l glucose (with or without insulin) (Fig. 4c) . Since in our HepG2 culture conditions, the transcription of HNF4A was not altered by TCF7L2, these data suggest that TCF7L2 may interfere directly with HNF4α protein expression.
Two specific TCF7L2 isoforms interact with HNF4α protein No direct TCF7L2 binding on the G6PC promoter region was reported in ChIP binding studies [21, [31] [32] [33] . Therefore, we hypothesised that TCF7L2 could regulate G6PC transcription by interacting with HNF4α protein. We immunoprecipitated HNF4α protein from whole-cell lysates to analyse a potential interaction with TCF7L2. After immunolabelling western blots with TCF7L2 antibodies, we observed a weak signal that suggested interaction of endogenous TCF7L2 proteins with HNF4α (data not shown). We then transfected HepG2 cells with the nine different TCF7L2 isoforms in the presence of 5 mmol/l glucose and 100 nmol/l insulin, and immunoprecipitated HNF4α from whole-cell lysates (ESM Fig. 4) . The co-immunoprecipitation assay shows that solely the long C-terminal TCF7L2 isoforms T6 and T8 co-immunoprecipitated with HNF4α. Next, we analysed T6-transfected HepG2 cells incubated with 1, 5 or 11 mmol/l glucose, and with or without insulin, conditions where endogenous T6 mRNA (represented by exons 12-15 assays) was also increased (Fig. 2a) . The western blot analyses of the coimmunoprecipitation assays show that the interaction of TCF7L2 with HNF4α was more pronounced in the presence of insulin and at higher glucose concentrations (Fig. 5b) , suggesting this represents a relevant control mechanism in liver glucose metabolism.
Discussion
We report a significant correlation between increased expression of alternative TCF7L2 liver transcripts and the type 2 diabetes-associated rs7901346 risk allele in obese normoglycaemic individuals. Such a correlation has also been found in other tissues important for glucose homeostasis (e.g. pancreas and adipose tissue [8, 9, 25] ), but a previous analysis in human liver samples [10] included fewer homozygous rs7901346 risk allele carriers and thus may have been underpowered to observe this correlation. Statistically, our study has a small sample size. Thus a larger size with a more stringent threshold for statistical significance may be needed to guarantee solid evidence against the null hypotheses. The observed association between the rs7901346 risk allele and increased TCF7L2 liver expression in obese normoglycaemic individuals was not observed in obese diabetic individuals. Our study suggests that having type 2 diabetes is associated with increased liver TCF7L2 transcript expression, although the functional causes of this association could not be assessed in our cross-sectional study. Another weakness is that we matched individuals within the normoglycaemic and diabetic groups, and were limited by the number, phenotypic characteristics of homozygous rs7901346 risk allele carriers, and individual diversity of the volunteers. We were unable to determine whether the regulation of TCF7L2 expression in livers of diabetic patients involved different mechanisms related to hyperglycaemia or insulin resistance, or whether the higher TCF7L2 expression levels were a consequence of other confounding factors such as differences in medication of type 2 diabetic individuals. Recent reports have shown that mouse TCF7L2 expression is insulin-responsive [20, 22] and that in insulin-resistant mice expression of the short and medium C-terminal transcripts (e.g. including T3 and T5) was reduced [21] . Our data on human liver transcript expression show that the expression of five liver TCF7L2 transcripts (T2, T4, T7, T8, T9) was increased in type 2 diabetic compared with normoglycaemic individuals. Furthermore, both short and long C-terminal TCF7L2 transcripts containing exon 13 (T2, T3, T4, T5, T7 and T9) were increased in a glucose dose-responsive manner in human HepG2 cells. Owing to the similar molecular masses of TCF7L2 protein isoforms, it is not clear which specific isoform is mainly induced by incubation of HepG2 cells with insulin. Indeed, our data may indicate that in type 2 diabetic individuals mRNA expression of the short C-terminal transcripts T3 and T5 in the liver is dysregulated, as expression of these transcripts was induced by high glucose in HepG2 cells, but not upregulated by high glucose levels in type 2 diabetic individuals.
Results from our siRNA experiments in HepG2 cells show that TCF7L2 inhibits a substantial number of genes involved in the human liver gluconeogenesis pathway, including the gene encoding the rate-limiting G6PC enzyme. Transcription of some genes may be directly regulated by TCF7L2 binding to their promoter and/or enhancer sequences, as has been reported for PCK1 and GYS2, while others (G6PC) have not been reported to have TCF7L2 recognition sites [21, [31] [32] [33] . Therefore, we analysed the role of TCF7L2 in the HNF4α-FOXO1-mediated transcriptional regulation of G6PC. Under our culture conditions, TCF7L2 affected HNF4α protein levels independently of any transcriptional regulation, suggesting a complex interaction with this major hepatic transcriptional regulator. Moreover, we report for the first time that solely TCF7L2 protein isoforms T6 and T8 interacted directly with HNF4α protein in human HepG2 cells cultured in 5 mmol/l glucose with 100 nmol/l insulin. The TCF7L2 isoform T6 contains the unique C-clamp sequence CRALF, while other isoforms (T3, T5, T8, T4 and T9) (Fig. 5a ). This C-clamp sequence does not alter the DNA-binding capacity of TCF7L2, but may affect its transcriptional activity [13, 34] . From the nine major human liver transcripts analysed by us [12] , the long isoforms T6 and T8 are the only C-clamp-containing proteins that lack exon 13, suggesting that this combination may permit HNF4α interaction. Protein sequence analysis predicted no domains/ motifs encoded by exon 13. Three other short isoforms containing the C-clamp domain without exon 13 have been reported (T-cell factor 4 alias of TCF7L2 [TCF4]S1, TCF4S4 and TCF4S6 [13] ), although they were not expressed in mouse liver tissue. These long and short transcripts were assessed by exon-junction 12-15 and 12-14 expression assays. The corresponding mRNA transcript expression levels slightly increased in HepG2 cells cultured in the presence of a high insulin concentration; however, this did not occur in a glucose-responsive manner as seen in exon 13-containing transcripts. This reveals a new and distinct role of particular C-terminal TCF7L2 isoforms in the pathogenic mechanisms leading to type 2 diabetes.
In conclusion, human alternative C-terminal TCF7L2 transcripts are induced in HepG2 cells by high glucose and insulin, and in liver of normoglycaemic individuals carrying the rs7901346 type 2 diabetes risk allele, as well as in diabetic individuals compared with normoglycaemic individuals (independently of their genotype). This suggests that these liver transcripts may play a role in the pathophysiology of type 2 diabetes. Two of the induced alternative mRNA transcripts encode TCF7L2 isoforms that bind to HNF4α and therefore may interfere with the transcriptional regulation of gluconeogenesis genes by HNF4α. These results underscore the importance of studying the regulation and function of alternative TCF7L2 transcripts with a view to characterising the role of TCF7L2 in the pathogenic mechanisms leading to type 2 diabetes. 
a b
Exon 12 Exon 13 Exon 14 / Exon 15 Exon
